Tom Jobe
Chief Operating Officer at SensiQ Technologies, USA
Title: New SPR-based biosensor platform for fragment-based-drug-discovery
Biography
Biography: Tom Jobe
Abstract
The detection and characterization of fragment binding events is dependent upon sensitive biophysical technologies capable of detecting low affinity interactions of low molecular weight compounds. Current Surface-Plasmon-Resonance based biosensors are limited in the processing and subsequent data analyses of fragment binding events. A new Surface Plasmon Resonance –based platform has been developed to specifically address binding analysis requirements in fragment screening. New injection techniques and data analysis methods illustrating rapid and automated hit selection capabilities will be presented. At the heart of the new platform is a new gradient concentration technique that allows affinity values to be obtained with single injections. Rapid hit selection identification is performed using a new statistical analysis method which allows data analysis to be competed in minutes. Relevant industry case studies will be highlighted to demonstrate fragment screening workflow optimization. The new platform potentially offers researchers a significant advancement in workflow and minimized assay development substantially over conventional SPR platforms used in fragment-based-drug-discovery.